307 related articles for article (PubMed ID: 25555992)
1. Sex differences in the relationship of IL-6 signaling to cancer cachexia progression.
Hetzler KL; Hardee JP; Puppa MJ; Narsale AA; Sato S; Davis JM; Carson JA
Biochim Biophys Acta; 2015 May; 1852(5):816-25. PubMed ID: 25555992
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6 and cachexia in ApcMin/+ mice.
Baltgalvis KA; Berger FG; Pena MM; Davis JM; Muga SJ; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2008 Feb; 294(2):R393-401. PubMed ID: 18056981
[TBL] [Abstract][Full Text] [Related]
3. Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.
Baltgalvis KA; Berger FG; Peña MM; Mark Davis J; White JP; Carson JA
J Appl Physiol (1985); 2010 Oct; 109(4):1155-61. PubMed ID: 20651218
[TBL] [Abstract][Full Text] [Related]
4. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK.
White JP; Puppa MJ; Gao S; Sato S; Welle SL; Carson JA
Am J Physiol Endocrinol Metab; 2013 May; 304(10):E1042-52. PubMed ID: 23531613
[TBL] [Abstract][Full Text] [Related]
5. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse.
White JP; Baynes JW; Welle SL; Kostek MC; Matesic LE; Sato S; Carson JA
PLoS One; 2011; 6(9):e24650. PubMed ID: 21949739
[TBL] [Abstract][Full Text] [Related]
6. Muscle oxidative capacity during IL-6-dependent cancer cachexia.
White JP; Baltgalvis KA; Puppa MJ; Sato S; Baynes JW; Carson JA
Am J Physiol Regul Integr Comp Physiol; 2011 Feb; 300(2):R201-11. PubMed ID: 21148472
[TBL] [Abstract][Full Text] [Related]
7. Ovarian function's role during cancer cachexia progression in the female mouse.
Hetzler KL; Hardee JP; LaVoie HA; Murphy EA; Carson JA
Am J Physiol Endocrinol Metab; 2017 May; 312(5):E447-E459. PubMed ID: 28292759
[TBL] [Abstract][Full Text] [Related]
8. Humanised antihuman IL-6R antibody with interferon inhibits renal cell carcinoma cell growth in vitro and in vivo through suppressed SOCS3 expression.
Oguro T; Ishibashi K; Sugino T; Hashimoto K; Tomita S; Takahashi N; Yanagida T; Haga N; Aikawa K; Suzutani T; Yamaguchi O; Kojima Y
Eur J Cancer; 2013 May; 49(7):1715-24. PubMed ID: 23274199
[TBL] [Abstract][Full Text] [Related]
9. Short-term pyrrolidine dithiocarbamate administration attenuates cachexia-induced alterations to muscle and liver in ApcMin/+ mice.
Narsale AA; Puppa MJ; Hardee JP; VanderVeen BN; Enos RT; Murphy EA; Carson JA
Oncotarget; 2016 Sep; 7(37):59482-59502. PubMed ID: 27449092
[TBL] [Abstract][Full Text] [Related]
10. Myofiber degeneration/regeneration is induced in the cachectic ApcMin/+ mouse.
Mehl KA; Davis JM; Berger FG; Carson JA
J Appl Physiol (1985); 2005 Dec; 99(6):2379-87. PubMed ID: 16288100
[TBL] [Abstract][Full Text] [Related]
11. Skeletal muscle function during the progression of cancer cachexia in the male Apc
VanderVeen BN; Hardee JP; Fix DK; Carson JA
J Appl Physiol (1985); 2018 Mar; 124(3):684-695. PubMed ID: 29122966
[TBL] [Abstract][Full Text] [Related]
12. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse.
Baltgalvis KA; Berger FG; Peña MM; Davis JM; White JP; Carson JA
Pflugers Arch; 2009 Mar; 457(5):989-1001. PubMed ID: 18712412
[TBL] [Abstract][Full Text] [Related]
13. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice.
Velázquez KT; Enos RT; Narsale AA; Puppa MJ; Davis JM; Murphy EA; Carson JA
J Nutr; 2014 Jun; 144(6):868-75. PubMed ID: 24759931
[TBL] [Abstract][Full Text] [Related]
14. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.
Bonetto A; Aydogdu T; Jin X; Zhang Z; Zhan R; Puzis L; Koniaris LG; Zimmers TA
Am J Physiol Endocrinol Metab; 2012 Aug; 303(3):E410-21. PubMed ID: 22669242
[TBL] [Abstract][Full Text] [Related]
15. SOCS3 modulates interleukin-6R signaling preference in dermal fibroblasts.
Luckett-Chastain LR; Ihnat MA; Mickle-Kawar BM; Gallucci RM
J Interferon Cytokine Res; 2012 May; 32(5):207-15. PubMed ID: 22313262
[TBL] [Abstract][Full Text] [Related]
16. Cachectic skeletal muscle response to a novel bout of low-frequency stimulation.
Puppa MJ; Murphy EA; Fayad R; Hand GA; Carson JA
J Appl Physiol (1985); 2014 Apr; 116(8):1078-87. PubMed ID: 24610533
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory signalling regulates eccentric contraction-induced protein synthesis in cachectic skeletal muscle.
Hardee JP; Counts BR; Gao S; VanderVeen BN; Fix DK; Koh HJ; Carson JA
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):369-383. PubMed ID: 29215198
[TBL] [Abstract][Full Text] [Related]
18. Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma-induced cachexia.
Puppa MJ; Gao S; Narsale AA; Carson JA
FASEB J; 2014 Feb; 28(2):998-1009. PubMed ID: 24145720
[TBL] [Abstract][Full Text] [Related]
19. Development of an UPLC mass spectrometry method for measurement of myofibrillar protein synthesis: application to analysis of murine muscles during cancer cachexia.
Lima M; Sato S; Enos RT; Baynes JW; Carson JA
J Appl Physiol (1985); 2013 Mar; 114(6):824-8. PubMed ID: 23329823
[TBL] [Abstract][Full Text] [Related]
20. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia.
Puppa MJ; White JP; Sato S; Cairns M; Baynes JW; Carson JA
Biochim Biophys Acta; 2011 Dec; 1812(12):1601-6. PubMed ID: 21914473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
